Generate Biomedicines, Inc. GENB
Set alert
13.87 USD +0.66 +5.01%
As of Nov 3, 1:52 PM ET
13.33 Day range 14.17
11.00 52-week range 22.67
- YTD
- +9.66%
- 1 year
- +9.66%
- Open
- 13.33
- Prev close
- 13.21
- Mkt cap
- 1.78B
- Vol
- 373.77K
- Avg vol
- 1.19M
- EPS
- -2.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.33
- High
- 14.17
- Forward P/E
- -5.79
- Beta
- 0.00
- Short ratio
- 7.37
- Inst. own
- 82.15%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 15.00
- 200-d avg
- 14.07
- 1y target
- 27.00
6M chart
Events in this range
- May 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- May 14, 2026Rating: Morgan Stanley · Overweight → Overweight
- Aug 6, 2026Earnings: -0.52; estimate -0.50833; surprise -2.3%
- Aug 28, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 5, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (36)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bearish | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 27, 2026 | 1 week ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| RSI: Overbought | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 3 months ago |
| SMA: Bearish | Aug 4, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
Newest 20 of 36.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.00 +94.6% upside
Now 13.87
- Target (low)
- 22.00
- Target (mean)
- 27.00
- Target (high)
- 30.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.545 | -0.67 – -0.44 | 0.00 | 0.0% | 7.75M | 0.0% | 4 |
| Next quarter | -0.5675 | -0.63 – -0.44 | 0.00 | 0.0% | 7.65M | 0.0% | 4 |
| Current year | -2.30 | -2.50 – -2.14 | 0.00 | 0.0% | 29.68M | 0.0% | 4 |
| Next year | -2.28 | -2.72 – -1.53 | -2.30 | +0.9% | 23.83M | -19.7% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 28, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 14, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 8, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Mar 24, 2026 | Goldman Sachs | Initiated | — | Buy |
| Mar 24, 2026 | Morgan Stanley | Initiated | — | Overweight |
| Mar 24, 2026 | Piper Sandler | Initiated | — | Overweight |
| Mar 24, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 24, 2026 | Guggenheim | Initiated | — | Buy |